In June of this year, the FDA approved the quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (Gardasil). The important fact about this vaccine is that it is intended to prevent diseases caused by HPV types 6, 11, 16, and 18—including cervical cancer, condyloma acuminata, and precancerous lesions associated with cervical adenocarcinoma in situ.